Xechem International Inc. (fka XKEM)

[smartmoney77]

This is big. This Dallas event has basically eliminated negators that try to claim this is a scam. Plus we should get some U.S. media coverage of the event itself later this month. The positive residual effect of this event is hard to measure but Xechem will gain enormous credibility as an investment vehicle here in the U.S. in my opinion.

I'm still looking for that pop to .04 and staying there before loan news even comes....


http://biz.yahoo.com/bw/060912/20060912005290.html?.v=1

Xechem Chairman, Dr. Ramesh Pandey, to Present NICOSAN(TM) Story at 34th Annual SCDAA Conference in Dallas
Tuesday September 12, 7:30 am ET


NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Sept. 12, 2006--Xechem International, Inc. (OTC BB: XKEM - News) announced today that its Chairman and CEO, Dr. Ramesh C. Pandey, has accepted an invitation to make a presentation on NICOSAN(TM), the Company's promising new sickle cell drug, at the Sickle Cell Disease Association of America's (SCDAA) 34th Annual Conference. The Conference will be held at the Hyatt Regency Hotel in Dallas, Texas, September 27th through September 30th, 2006. More than 500 physicians, researchers, scientists, nurses and others in the medical community from throughout the country and around the world are expected to attend the Conference, which is also expected to draw a number of sickle cell patients and their family members.
ADVERTISEMENT


Dr. Pandey will speak as part of a Special Panel entitled "Treatment Options and Clinical Trials" on "The Nigerian Experience in the Development of a New Anti-Sickling Natural Herbal Drug." The Company will also set up a poster presentation during the Conference that will afford Xechem the opportunity to present to delegates the credible scientific and medical data that demonstrate both the efficacy and non-toxicity of NICOSAN(TM) (named HEMOXIN(TM) in the US).

According to Dr. Pandey, "It is a fortunate coincidence that this prestigious conference is being held so soon after NICOSAN(TM) was approved by Nigerian drug regulators, National Agency for Food and Drug Administration and Control (NAFDAC) and launched in Nigeria for sale on July 6th, 2006, by His Excellency, Chief Olusegun Obasanjo, GCFR, the President and Commander-in-Chief of the Armed Forces of the Federal Republic of Nigeria. I look forward to presenting to the Conference delegates a summary of the very positive developments regarding what we feel is a truly historic drug. Given the few treatment options currently available for sickle cell sufferers, and the proven efficacy and safety of this drug, I have no doubt that the presentation will be favorably received by those in attendance."

About Sickle Cell Disease

Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn can cut off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks or "crises", damage to various organs and shortened life spans. People with SCD often suffer unpredictable painful crises several times a year lasting from a few hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, with an estimated 10 - 12 million sufferers throughout the African continent. Worldwide, at least 16 million individuals are believed to be afflicted with SCD.

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward looking statements involve known and unknown risks and uncertainties.



Contact:
Xechem International, Inc.
Stephen Burg, 707-425-8855

--------------------------------------------------------------------------------
Source: Xechem International, Inc.